Binimetinib (an MEK1/2 inhibitor) and the STK19 kinase inhibitor chelidonine were described to be relatively effective in NRAS-mutated melanomas [84,85], although controversies were raised against the efficacy of the STK19 inhibitor [86]. Here, NRAS is linked to melanoma.